Market Overview

XTL Biopharma Buys Stake in Proteologics from Teva

Related TEVA
Benzinga's M&A Chatter for Tuesday November 18, 2014
The Top 25 Analysts On Wall Street
Sofinnova Ventures Closes $500M Fund (Fox Business)

XTL Biopharmaceuticals Ltd. announced on November 21^st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium). The Shares represent all of Teva's shares in Proteologics and represent approximately 31.35% of Proteologics issued and outstanding share capital.

Posted-In: News Asset Sales

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters